Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;17(12):658.
doi: 10.1038/s41585-020-00398-1.

Combined immune checkpoint inhibition for high-risk urothelial carcinoma

Rebecca Tregunna  1
Affiliations
Comment

Combined immune checkpoint inhibition for high-risk urothelial carcinoma

Rebecca Tregunna. Nat Rev Urol. 2020 Dec.
No abstract available

PubMed Disclaimer

Comment on

  • Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
    Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Gao J, et al. Nat Med. 2020 Dec;26(12):1845-1851. doi: 10.1038/s41591-020-1086-y. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046869 Free PMC article. Clinical Trial.

References

Original article
    1. Gao, J. et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. https://doi.org/10.1038/s41591-020-1086-y (2020) - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources